ABVC — ABVC Biopharma Income Statement
0.000.00%
Last trade - 00:00- $70.96m
- $74.16m
- $0.51m
- 30
- 12
- 84
- 36
Annual income statement for ABVC Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.483 | 0.356 | 0.97 | 0.152 | 0.51 |
| Cost of Revenue | |||||
| Gross Profit | 0.464 | 0.351 | 0.683 | -0.15 | 0.509 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 9.95 | 12.1 | 16.2 | 6.92 | 4.96 |
| Operating Profit | -9.47 | -11.7 | -15.2 | -6.77 | -4.45 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -10.8 | -11.2 | -15.5 | -8.02 | -5.37 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -10.6 | -12 | -16.3 | -8.28 | -5.26 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -9.79 | -12.8 | -16.4 | -7.79 | -4.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -9.79 | -12.8 | -16.4 | -7.79 | -4.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -4.65 | -5.12 | -5.16 | -1.8 | -0.434 |